| Not Yet Recruiting | Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis NCT07424950 | United Lincolnshire Hospitals NHS Trust | Phase 2 |
| Not Yet Recruiting | Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts NCT07498205 | SWOG Cancer Research Network | Phase 4 |
| Recruiting | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Vir NCT07020533 | City of Hope Medical Center | Phase 1 |
| Not Yet Recruiting | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias NCT07447817 | John Mascarenhas | Phase 2 |
| Not Yet Recruiting | Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Mye NCT07521046 | University of Utah | Phase 1 |
| Not Yet Recruiting | A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myel NCT07250646 | Aspera Biomedicines, Inc. | Phase 1 |
| Recruiting | To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects NCT07480824 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Therapeutic RSK1 Targeting in Myelofibrosis NCT07379125 | Washington University School of Medicine | Phase 1 |
| Recruiting | Momelotinib During and After HCT in Myelofibrosis NCT07104799 | Massachusetts General Hospital | Phase 1 |
| Recruiting | Registry Platform Myelofibrosis and Anemia NCT06976918 | iOMEDICO AG | — |
| Recruiting | Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibros NCT06781099 | Hospices Civils de Lyon | N/A |
| Recruiting | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225 | MPN Research Foundation | — |
| Recruiting | Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Mar NCT07281781 | University of California, Irvine | Phase 1 / Phase 2 |
| Active Not Recruiting | Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutati NCT07342712 | First Affiliated Hospital of Zhejiang University | — |
| Recruiting | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxi NCT06859424 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Not Yet Recruiting | Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History NCT06923670 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition NCT06605586 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 1 / Phase 2 |
| Recruiting | A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis NCT06773195 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Clinical Epidemiology in Contemporary Patients With Myelofibrosis. NCT06533813 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | — |
| Completed | To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects NCT06598956 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly NCT06345495 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral NCT06398457 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Recruiting | RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis NCT06397313 | Ryvu Therapeutics SA | Phase 2 |
| Withdrawn | A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients W NCT06619522 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Pat NCT06059391 | City of Hope Medical Center | Phase 2 |
| Unknown | A Safety and Tolerability Study of Jaktinib NCT05279001 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 |
| Recruiting | Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Subop NCT06479135 | Kartos Therapeutics, Inc. | Phase 3 |
| Recruiting | A Study of GLB-001 in Patients With Myeloid Malignancies NCT06378437 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) NCT06351631 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | A Telehealth Advance Care Planning Intervention NCT05875805 | University of Rochester | N/A |
| Terminated | A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) NCT06245941 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytope NCT05980806 | Karyopharm Therapeutics Inc | Phase 2 |
| Recruiting | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, NCT06063486 | University of Southern California | Phase 2 |
| Recruiting | Haplo-HSCT for Myelofibrosis NCT06674382 | Peking University People's Hospital | N/A |
| Recruiting | A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) NCT06122831 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantati NCT06001385 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Completed | Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditio NCT06132243 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 |
| Recruiting | 18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study. NCT06164561 | First Affiliated Hospital of Zhejiang University | — |
| Completed | A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets NCT06024915 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myel NCT05535764 | University of Utah | Phase 1 |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Clonal Architecture of ASXL1-mutated Myelofibrosis NCT05710211 | University Hospital, Angers | N/A |
| Recruiting | Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm NCT05025488 | Marina Kremyanskaya | Phase 1 |
| Unknown | Ruxolitinib in Patients With Myelofibrosis NCT05762874 | Assiut University | — |
| Recruiting | Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs NCT05423691 | Cellenkos, Inc. | Phase 1 |
| Recruiting | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies NCT05488548 | Epigenetix, Inc. | Phase 1 |
| Unknown | Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis NCT05569538 | The University of Hong Kong | Phase 2 |
| Unknown | Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis NCT04709458 | Taiga Biotechnologies, Inc. | Phase 1 |
| Completed | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participan NCT05444972 | AbbVie | — |
| Terminated | TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients NCT06388759 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Active Not Recruiting | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms NCT05455294 | Jacqueline Garcia, MD | Phase 1 |
| Recruiting | Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002 NCT05233618 | Karen Ballen, MD | Phase 1 |
| Unknown | A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis NCT05447260 | Qilu Hospital of Shandong University | Phase 4 |
| Recruiting | Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a NCT05280509 | Telios Pharma, Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia NCT05320198 | Disc Medicine, Inc | Phase 1 / Phase 2 |
| Recruiting | Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera NCT06516406 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Comb NCT05371964 | Geron Corporation | Phase 1 |
| Completed | A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib NCT07357441 | Novartis Pharmaceuticals | — |
| Recruiting | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms NCT05123365 | University of California, Irvine | Phase 1 / Phase 2 |
| Recruiting | A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis NCT05037760 | Takeda | Phase 2 |
| Recruiting | Two Step Haplo With Radiation Conditioning NCT05031897 | Thomas Jefferson University | Phase 2 |
| Terminated | Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. NCT04866056 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Unknown | Ropeginterferon Alfa 2b for Early Myelofibrosis NCT04988815 | The University of Hong Kong | Phase 2 |
| Recruiting | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CM NCT04771572 | Newave Pharmaceutical Inc | Phase 1 |
| Completed | A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib NCT05665192 | Bristol-Myers Squibb | — |
| Completed | Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment. NCT04851535 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 |
| Completed | To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects NCT05982106 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Completed | To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With P NCT04629508 | Incyte Corporation | Phase 2 |
| Completed | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candid NCT05972577 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Particip NCT04679870 | Galecto Biotech AB | Phase 2 |
| Withdrawn | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis Af NCT03602898 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Sub NCT04551053 | Incyte Corporation | Phase 3 |
| Terminated | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER- NCT04551066 | Incyte Corporation | Phase 3 |
| Terminated | Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis NCT04543279 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk My NCT04576156 | Geron Corporation | Phase 3 |
| Active Not Recruiting | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) NCT04603495 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib o NCT04817007 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated M NCT04562870 | Karyopharm Therapeutics Inc | Phase 2 |
| Active Not Recruiting | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis NCT04562389 | Karyopharm Therapeutics Inc | Phase 3 |
| Active Not Recruiting | A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib NCT04640025 | Incyte Corporation | Phase 2 |
| Active Not Recruiting | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neop NCT04717414 | Celgene | Phase 3 |
| Active Not Recruiting | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neop NCT04279847 | Incyte Corporation | Phase 1 |
| Unknown | Methods of T Cell Depletion Trial (MoTD) NCT04888741 | University of Birmingham | Phase 2 |
| Completed | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT NCT04629430 | University of Virginia | N/A |
| Completed | Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 NCT04676529 | Syntara | Phase 1 / Phase 2 |
| Completed | Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis NCT04617028 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 |
| Unknown | Haplo-identical Transplantation in Patients With Myelofibrosis - A Phase 2 Prospective Multicentric Prospectiv NCT04728490 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Unknown | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib i NCT04485260 | Kartos Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy NCT04354727 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Withdrawn | Study of Select Combinations in Adults With Myelofibrosis NCT04283526 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intoleran NCT04640532 | Kartos Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis NCT04655118 | Telios Pharma, Inc. | Phase 2 |
| Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer NCT04666025 | City of Hope Medical Center | — |
| Completed | Actuate 1901: 9-ING-41 in Myelofibrosis NCT04218071 | Actuate Therapeutics Inc. | Phase 2 |
| Active Not Recruiting | Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis NCT04217356 | University Health Network, Toronto | — |
| Withdrawn | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation NCT04464889 | Medigene AG | Phase 1 |
| Recruiting | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant NCT03964506 | Omar Aljitawi | EARLY_Phase 1 |
| Active Not Recruiting | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers NCT04328844 | iOnctura | Phase 1 |
| Recruiting | A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis NCT04176198 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation NCT04060277 | City of Hope Medical Center | Phase 2 |
| Completed | European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study NCT04153305 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | — |
| Terminated | Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients NCT04097821 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermedi NCT03952039 | Celgene | Phase 3 |
| Active Not Recruiting | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT NCT03912064 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythem NCT03755518 | Celgene | Phase 3 |
| Completed | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myelop NCT03878199 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies NCT02530034 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis. NCT03886415 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 |
| Withdrawn | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Bloo NCT03438344 | City of Hope Medical Center | Phase 2 |
| Completed | The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase NCT03907436 | University of California, Irvine | N/A |
| Active Not Recruiting | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Diso NCT03289910 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. NCT03427866 | Massachusetts General Hospital | Phase 2 |
| Active Not Recruiting | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Tran NCT03560752 | City of Hope Medical Center | Phase 1 |
| Completed | CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms NCT03566446 | Inge Marie Svane | Phase 1 |
| Active Not Recruiting | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) NCT03645824 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| Terminated | Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis NCT03373877 | Samus Therapeutics, Inc. | Phase 1 |
| Completed | Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) NCT03745378 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | — |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Active Not Recruiting | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression NCT03480360 | Dartmouth-Hitchcock Medical Center | Phase 3 |
| Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774 | Massive Bio, Inc. | — |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia NCT02730884 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) NCT03136185 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Phase 1 / Phase 2 |
| Withdrawn | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferati NCT02564536 | Washington University School of Medicine | Phase 1 |
| Unknown | Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy NCT03959371 | Margherita Maffioli | — |
| Active Not Recruiting | A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosi NCT03069326 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636 | Masonic Cancer Center, University of Minnesota | N/A |
| Recruiting | Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis NCT02934477 | Center for International Blood and Marrow Transplant Research | — |
| Completed | Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis NCT02784496 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG NCT02916979 | Dartmouth-Hitchcock Medical Center | Phase 1 |
| Terminated | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Pa NCT02877082 | Emory University | Phase 2 |
| Withdrawn | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelof NCT02805868 | Northwestern University | EARLY_Phase 1 |
| Withdrawn | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders NCT02663648 | Shandong University | — |
| Completed | Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg NCT02742324 | French Innovative Leukemia Organisation | Phase 1 / Phase 2 |
| Completed | Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) NCT02268253 | Stemline Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HS NCT02728700 | Stanford University | Phase 1 |
| Completed | A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of NCT02593760 | Hoffmann-La Roche | Phase 1 |
| Completed | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malig NCT02556931 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV a NCT02506933 | City of Hope Medical Center | Phase 2 |
| Completed | Reduced Intensity Conditioning Transplant Using Haploidentical Donors NCT02581007 | Northside Hospital, Inc. | Phase 2 |
| Unknown | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia NCT02530619 | Northwestern University | N/A |
| Completed | URMC Related Haplo-identical Donor BMT NCT02660281 | University of Rochester | Phase 1 |
| Completed | Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Mye NCT02426086 | Geron Corporation | Phase 2 |
| Completed | Intra-Osseous Co-Transplant of UCB and hMSC NCT02181478 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea NCT02493530 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Terminated | iCare for Cancer Patients NCT02435550 | University of Florida | N/A |
| Terminated | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as NCT02436135 | Gilead Sciences | Phase 1 |
| Completed | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies NCT02396134 | City of Hope Medical Center | Phase 2 |
| Completed | Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibros NCT02370706 | Novartis Pharmaceuticals | Phase 1 |
| Withdrawn | Ruxolitinib in Combination With Autotransplant NCT02469974 | Marina Kremyanskaya | N/A |
| Terminated | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685 | Asana BioSciences | Phase 1 / Phase 2 |
| Completed | Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Rel NCT02167958 | Rafic Farah, MD | Phase 1 |
| Completed | Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects NCT02765724 | CTI BioPharma | Phase 1 |
| Recruiting | Quantitative MRI for Myelofibrosis NCT01973881 | University of Michigan Rogel Cancer Center | — |
| Completed | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Tr NCT02129582 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subject NCT02807077 | CTI BioPharma | Phase 1 |
| Completed | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative NCT02158858 | Constellation Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis NCT02065154 | University of Alabama at Birmingham | Phase 2 |
| Completed | Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation The NCT01956799 | Fondazione Italiana Sindromi Mielodisplastiche-ETS | — |
| Completed | Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia NCT01712308 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) NCT01693601 | John Mascarenhas | Phase 1 / Phase 2 |
| Terminated | Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis NCT01758588 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Terminated | A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in P NCT01730248 | Novartis Pharmaceuticals | Phase 1 |
| Completed | JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis NCT01795677 | French Innovative Leukemia Organisation | Phase 2 |
| Completed | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders NCT01758042 | Massachusetts General Hospital | N/A |
| Completed | Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia V NCT01692366 | Bristol-Myers Squibb | Phase 2 |
| Completed | Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis NCT02910258 | University Hospital, Brest | — |
| Completed | Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis NCT05410470 | Qilu Hospital of Shandong University | — |
| Completed | Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms NCT01520220 | Eli Lilly and Company | Phase 1 |
| Completed | INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythe NCT01493414 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Clinical and Pathophysiological Investigations Into Erdheim Chester Disease NCT01417520 | National Human Genome Research Institute (NHGRI) | — |
| Completed | Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myel NCT01814475 | Gruppo Italiano Trapianto di Midollo Osseo | Phase 2 |
| Completed | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients NCT01398462 | JW Pharmaceutical | Phase 1 |
| Completed | Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocyth NCT01369498 | Gilead Sciences | Phase 2 |
| Completed | Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post- NCT01317875 | Incyte Corporation | Phase 1 |
| Completed | Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients NCT01340651 | Incyte Corporation | Phase 2 |
| Terminated | Anti-TGF-beta Therapy in Patients With Myelofibrosis NCT01291784 | John Mascarenhas | Phase 1 |
| Terminated | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation NCT01300611 | Tarix Pharmaceuticals | Phase 1 |
| Completed | Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza NCT01290302 | American Regent, Inc. | Phase 1 |
| Completed | Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis NCT01149681 | PharmaMar | Phase 2 |
| Completed | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloa NCT00975975 | Indiana University School of Medicine | Phase 2 |
| Completed | Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States NCT00997386 | University of Arizona | Phase 2 |
| Completed | Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II NCT00934544 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies NCT00807677 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies NCT00719836 | S*BIO | Phase 1 / Phase 2 |
| Completed | A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis NCT00745550 | S*BIO | Phase 1 / Phase 2 |
| Completed | A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis NCT00724334 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Bone Marrow Transplant Chart Review for RIC NCT00723333 | University of Utah | — |
| Unknown | CEP-701 (Lestaurtinib) in Myelofibrosis NCT00668421 | Ronald Hoffman | Phase 1 / Phase 2 |
| Terminated | Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis NCT00667277 | Ronald Hoffman | Phase 2 |
| Completed | Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis NCT00572065 | Weill Medical College of Cornell University | EARLY_Phase 1 |
| Completed | A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelof NCT00631462 | TargeGen | Phase 1 |
| Terminated | In-Vivo Activated T-Cell Depletion to Prevent GVHD NCT00594308 | Indiana University | N/A |
| Terminated | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in NCT00852709 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Research Tissue Bank NCT00666549 | Icahn School of Medicine at Mount Sinai | — |
| Terminated | A Safety Study of XL019 in Adults With Myelofibrosis NCT00522574 | Exelixis | Phase 1 |
| Completed | Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis NCT00572897 | John Mascarenhas | Phase 2 |
| Completed | CEP-701 for PH-negative Myelofibrosis NCT00494585 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thromb NCT00509899 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia NCT00463385 | Celgene | Phase 2 |
| Completed | Correlative Biomarker Study in Patients With Myeloproliferative Disorders NCT00665067 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in NCT04282421 | Central Hospital, Nancy, France | — |
| Terminated | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias NCT00522990 | Astex Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Terminated | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor NCT00393380 | The Emmes Company, LLC | Phase 2 |
| Completed | Lenalidomide for Patients With Myelofibrosis (MF) NCT00352794 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes NCT00715247 | University of Utah | — |
| Completed | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplas NCT00360035 | Gemin X | Phase 2 |
| Completed | A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM) NCT00287261 | Universitaire Ziekenhuizen KU Leuven | Phase 2 |
| Completed | Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome NCT00475020 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient NCT00719888 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) NCT00255346 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overl NCT00235391 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants NCT00606437 | Duke University | Phase 1 |
| Completed | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases NCT00309842 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Ph II Study of Azacitidine in Myelofibrosis NCT00569660 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant NCT00354120 | Gruppo Italiano Trapianto di Midollo Osseo | Phase 2 / Phase 3 |
| Completed | A Phase II Study of CC-5013 in Myelofibrosis NCT00087672 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leu NCT00081874 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Genetic Analysis of Gray Platelet Syndrome NCT00069680 | National Human Genome Research Institute (NHGRI) | — |
| Withdrawn | Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With A NCT00148980 | Hadassah Medical Organization | Phase 2 |
| Completed | Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients NCT00599547 | Universitätsklinikum Hamburg-Eppendorf | Phase 2 |
| Completed | A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) NCT00136409 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies NCT01499147 | University of Illinois at Chicago | N/A |
| No Longer Available | Expanded Access to Navitoclax NCT03592576 | AbbVie | — |
| No Longer Available | Managed Access Program for Momelotinib in Myelofibrosis NCT05582083 | GlaxoSmithKline | — |
| Available | Individual Patient Compassionate Use of Fedratinib NCT03723148 | Celgene | — |
| Available | Karyopharm Expanded Access Program for Selinexor NCT07215832 | Karyopharm Therapeutics Inc | — |